AGIO agios.com Earnings growth forecast for next year

Corporate emblem and logo of Agios Pharmaceuticals, Inc. (AGIO)

Agios Pharmaceuticals (AGIO) relies on transparent capital management and deep expertise in metabolic therapy. Its status as a scientific pioneer in treating rare pathologies positions the company as an industry leader, which is supported by the EPS growth forecasting model for the coming year. Expansion into orphan blood markets is broadening the customer base, while 42.10 reflects the current volume of the expected profit metric.

Agios Pharmaceuticals Inc (AGIO): Expected net earnings per share growth next year from 07/04/2022 to 11/15/2026

AGIO (Agios): analytical breakdowns and indicator data

- share price and consensus valuation forecast:
Initial company analysis:AGIO, agios.com
Finished products of Agios Pharmaceuticals, Inc.

To minimize fundamental risks, investors should select assets with a stable consensus earnings forecast. This indicator aggregates expert estimates of EPS dynamics for the upcoming period, reflecting the balance between institutional calculation and market optimism. In the case of Agios Pharmaceuticals (AGIO), the projected growth in earnings per share for year n+1 confirms the monetization of its monopoly position in the therapy of rare metabolic pathologies via a unique research platform.

Analysis of competing companies

ASND (Ascendis) - Earnings growth forecast for next year|Earnings growth forecast for next year Madrigal Pharmaceuticals|Earnings growth forecast for next year CORT|Net earnings per share growth forecast for next year RYTM (Rhythm Pharma)|Net earnings per share growth forecast for next year akerotx.com AKRO|Metsera Therapeutics (MTSR) - Expected net earnings per share growth next year|MLTX - Net earnings per share growth forecast for next year|CRNX: Net earnings per share growth forecast for next year|NAMS: Earnings growth forecast for next year|SLNO - Consensus forecast of earnings per share growth for next year|Net earnings per share growth forecast for next year Amicus Corp|89bio Pharma (ETNB) - Consensus forecast of earnings per share growth for next year|Net earnings per share growth forecast for next year structuretx.com (GPCR)|Expected earnings per share growth for next year mimedx.com MDXG|Net earnings per share growth forecast for next year Rezolute RZLT|Lexicon Pharmaceuticals, Inc. - Net earnings per share growth forecast for next year|MBX: Expected earnings per share growth for next year|Altimmune Corp - Projected earnings per share increase next year|Aardvark Therapeutics Inc (AARD) - Net earnings per share growth forecast for next year|Net earnings per one share growth forecast for next year Sagimet Biosciences SGMT|BIOA (bioagelabs.com) - Earnings growth forecast for next year|Expected earnings per share growth for next year Biomea Fusion (BMEA)|Earnings growth forecast for next year QNCX|Projected earnings per share increase next year GUTS|Earnings growth forecast for next year VTVT (vTv Therapeutics Inc.)|Expected earnings per share trend next year ATPC|Pluristem Therapeutics - Earnings growth forecast for next year|Consensus forecast of earnings per share growth for next year synlogictx.com SYBX|LPCN: Earnings growth forecast for next year|Matinas BioPharma Holdings, Inc. - Expected earnings per share trend next year|SPRB (Spruce Biosciences Inc.) - Earnings growth forecast for next year|galecto.com (GLTO) - Consensus forecast of earnings per share growth for next year|Net earnings per share growth forecast for next year Carmell Therapeutics (CTCX)|LUMO (Lumos Pharma Inc) - Expected earnings per share trend next year|Net earnings per share growth forecast for next year organovo.com ONVO|Radius Health (RDUS) - Expected net earnings per share growth next year